英文药名：Pixuvri solution infusion（pixantrone dimaleate）
中文药名：匹杉琼冻干粉注射剂
生产厂家：CTI Life Sciences Limited
药品介绍
Pixuvri（pixantrone）注射剂扩大批准适应症用于淋巴瘤
Pixuvri（pixantrone）将为医师增加一个重要的治疗选择，也将为患者产生有意义的影响。
Pixuri被批准用于治疗多次复发或难治性侵袭性非霍奇金B细胞淋巴瘤患者的治疗。pixantrone（Pixuvri）是蒽环类化疗药物家族中的一员。
Pixuri目前用于复发性、侵袭性非何杰金淋巴瘤（NHL）的治疗。I/II期临床研究显示，pixantrone（Pixuvri）单一用药的疾病完全缓解率达到20%，当pixantrone（Pixuvri）替换了标准治疗药物CHOP（环磷酰胺+多柔比星+长春新碱+泼尼松）中的多柔比星时，疾病的完全缓解率达到59%.III期临床也获得了肯定结果。
对于本品的潜在治疗领域包括各种何杰金恶性瘤、实体瘤和免疫疾病，研究者期望pixantrone（Pixuvri）能提高蒽环类药物的安全性和有效性。标准治疗药物蒽环霉素已显示出治疗癌症的强有效性，但蒽环霉素总是与累积心脏损伤相关，这大大缩减了蒽环霉素的使用范围。
pixantrone（Pixuvri）较蒽环霉素更易于服药。而且，迄今为止还未发现pixantrone（Pixuvri）有严重的心脏不良反应。pixantrone（Pixuvri）将朝着减少心脏毒性、增加治疗有效性和方便患者用药的方向发展。
包装规格
注：除德国50MG/bottle以外，欧洲其他的国家包装都是29MG/bottle，采购以在线咨询为准!
PIXUVRI*29MG IV 1FL
NOME COMMERCIALE PIXUVRI*29MG IV 1FL
AZIENDA CTI Life Sciences Limited
CLASSE C
RICETTA OSP - medicinale soggetto a prescrizione medica limitativa, utilizzabile esclusivamente in ambiente ospedaliero o in struttura ad esso assimilabile - vietata la vendita al pubblico
PRINCIPIO ATTIVO pixantrone
Packaging: 29 mg powder for concentrate for solution for infusion.
About Pixuvri (pixantrone)
Pixuvri is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, Pixuvri inhibits Topo-isomerase II but unlike anthracyclines—rather than intercalation with DNA-Pixuvri alkylates DNA—forming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in Pixuvri in an effort to prevent the binding of iron and perpetuation of superoxide production — both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large cell lymphoma without unacceptable rates of cardiotoxicity.